• 中国核心期刊(遴选)数据库收录期刊
  • 中文科技期刊数据库收录期刊
  • 中国期刊全文数据库收录期刊
  • 中国学术期刊综合评价数据库统计源期刊等

快速检索引用检索图表检索高级检索

• 投稿 • 上一篇    下一篇

腹腔镜与开腹手术治疗早期卵巢癌的临床疗效比较

温梅梅   

  1. (中国人民解放军第九五医院妇科,莆田 351100)
  • 收稿日期:1900-01-01 修回日期:1900-01-01 出版日期:2016-10-25

Comparison of the Clinical Effect of Laparoscopic and Open Surgery in the Treatment of Early Ovarian Cancer

Wen Mei-mei   

  1. (Department of Gynecology,The Chinese People's Liberation Army No. nine Five Hospital,Putian 351100, China)
  • Received:1900-01-01 Revised:1900-01-01 Online:2016-10-25

摘要: 【摘要】目的:分析腹腔镜与开腹手术治疗早期卵巢癌的临床疗效。方法:以78例早期卵巢癌患者为研究对象,39例采用腹腔镜治疗,39例使用开腹手术治疗,对比两组患者术中和术后情况。结果:腹腔镜组患者的手术时间和术中出血量低于对照组,淋巴结切除数多于对照组,术中出血量差异显著(P<0.05),手术时间和淋巴结切除数差异不显著。腹腔镜组术后肛门通气和住院时间、术后发热和并发症发生率、术后化学治疗(化疗)例数比例低于开腹手术组,术后肛门排气时间、住院时间、术后发热及并发症发生率差异有统计学意义(P<0.05),术后化疗例数差异无统计学意义(P>0.05)。结论:腹腔镜治疗早期卵巢的近期疗效优于开腹手术,且安全可靠,可作为治疗早期卵巢癌的首选方法。

Abstract: 【ABSTRACT】Objective: To analyze the clinical effect of laparoscopic and open surgery in the treatment of early ovarian cancer. Methods:78 cases of early ovarian cancer patients were studied,39 cases were treated by laparoscopy,39 cases were treated by open surgery, and the cases were compared with two groups of patients. Results:The patients in the laparoscopic group the operative time and blood loss less than control group, lymph node resection counts more than the control group, intraoperative bleeding volume difference significant (P<0.05), the operation time and lymph node resection differences not significant. Laparoscopic postoperative anus ventilation and hospitalization time, postoperative fever and complications occurrence rate, postoperative chemotherapy proportion is lower than the open surgery group, postoperative anal exhaust time, hospitalization time, postoperative fever and complications occurrence rate difference was statistically significant (P<0.05) and postoperative chemotherapy the number difference no statistical significance (P>0.05). Conclusion:Laparoscopic treatment of early ovarian surgery is better than open surgery, and safe and reliable, can be used as the first choice for the treatment of ovarian cancer.